Among the most anticipated candidates from the Korean pharmaceutical pipepline are SK Biopharm’s sleep disorder drug and epilepsy drug, reports Pulse.

The sleep disorder drug SKL-N05 is on track for an FDA application at the end of this year with a goal of a market launch next year after a phase III study was recently completed.